Follow The Filings

RNTX Rein Therapeutics

Rein Therapeutics earnings company data as of 4:48 AM ET 10/23

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS — — —
Rev — — —
FY2026 Q2 14 Aug EPS — -0.10 —
Rev — — —

Insider trades

Open-market buys and sales by RNTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RNTX insider trades
  • $626K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Josef H Von Rickenbach Director
    Buy
    $50K 47,060 shares at $1.05 +305% to stake
    Traded May 21–27 Filed May 28
    ↗
  2. James Brian Windsor See Remarks
    Buy
    $25K 25,000 shares at $1.00 +1222% to stake
    Traded Apr 30 Filed May 13
    ↗
  3. Voss Capital, LP 10% owner, +4 joint filers
    Buy
    $128K 104,183 shares at $1.22 +13% to stake
    Traded Nov 14, 2025 Filed Nov 18, 2025
    ↗
  4. Voss Capital, LP 10% owner, +4 joint filers
    Buy
    $423K 306,050 shares at $1.38 +158% to stake
    Traded Oct 24–28 Filed Oct 28, 2025
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
8-K 3.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
S-1 Filing Doc
10-K/A Filing Doc
10-K Filing Doc
8-K 1.01,2.03,3.02,9.01 Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,2.03,3.02,9.01 Filing Doc
8-K 1.02 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.